Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Shree Ganesh Remedies's Enterprise Value is ₹8,173 Mil.
Shree Ganesh Remedies's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, Shree Ganesh Remedies's EV-to-FCF for today is .
The historical rank and industry rank for Shree Ganesh Remedies's EV-to-FCF or its related term are showing as below:
BOM:540737'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 116.2
Current: 116.2
During the past 13 years, the highest EV-to-FCF of Shree Ganesh Remedies was 116.20. The lowest was 0.00. And the median was 0.00.
BOM:540737's EV-to-FCF is ranked worse than 88.77% of 570
companies
in the Drug Manufacturers industry
Industry Median: 20.645
vs BOM:540737: 116.20
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shree Ganesh Remedies's PE Ratio (TTM) for today is calculated as:
Shree Ganesh Remedies's share price for today is ₹633.00.
Shree Ganesh Remedies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹13.830.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shree Ganesh Remedies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shree Ganesh Remedies EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shree Ganesh Remedies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Shree Ganesh Remedies's EV-to-FCF falls into.
Shree Ganesh Remedies's current Enterprise Value is ₹8,173 Mil.
Shree Ganesh Remedies's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Shree Ganesh Remedies (BOM:540737) Overvalued in 2026?
Based on GuruFocus' analysis, Shree Ganesh Remedies stock appears to be overvalued.
The current stock price of ₹633.00 is trading 6.8% above its estimated GF Value™ of ₹592.68.
GuruFocus considers Shree Ganesh Remedies to be Fairly Valued.
Key valuation signals for BOM:540737:
EV-to-FCF:
GF Value™: ₹592.68 vs. price of ₹633.00 (6.8% above fair value)
No single metric tells the full story. See the BOM:540737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shree Ganesh Remedies Ltd manufactures drug intermediates, chemicals, and specialty fine chemicals for the pharmaceutical industry. The company offers pharmaceutical and specialty chemical products, including Trityl chloride, Furoyl chloride, and Dinitolmide. The company's business falls under the primary segment of Bulk Drug Intermediaries.
85GF Score
Get the complete analysis for BOM:540737
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540737 has been successfully added to your 
